Novel Drug/Biologics Delivery Systems FDA Workshop Slated For July 8
This article was originally published in The Gray Sheet
Executive Summary
FDA is soliciting feedback on regulatory challenges posed by novel drug and biologics delivery systems - and steps the agency can take to ease their regulatory pathway